In addition, the co-expression has been identified in cancer cell lines derived from different cancer types including bladder, head and neck squamous, prostate, and ovarian cancers [56]–[59], suggesting that Y-142 may be able to exert its synergistic anti-cancer activity against these cancer types by neutralizing sHB-EGF and ARG functionalities simultaneously. Here, EGF is linked to ovarian carcinoma.